-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh Pharma expands Roche partnership to develop cancer therapies

PUBT·10/19/2026 10:22:34
Listen to the news
Hansoh Pharma expands Roche partnership to develop cancer therapies
  • Hansoh Pharma entered a second ADC collaboration with Roche on October 19, 2026, covering two preclinical programs and additional Roche-proposed targets.
  • Payments include USD 400 million upfront and USD 110 million on the first anniversary.
  • Potential milestone payments exceed USD 15 billion, with tiered royalties on future product sales.
  • Roche takes over development after Phase Ia outside mainland China, Hong Kong, Macau and Taiwan; Hansoh retains rights in those markets.
  • An option allows co-development of up to two programs outside those markets for additional U.S. commercialization upside.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.